All In Biotech

Drug Trial Radar · NCT01677910

TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)

A Phase 3, Randomized, Placebo-controlled, Parallel Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog (SSA) Therapy

Last checked: Nov 20, 2026Latest source record: Feb 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 135 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

135

Actual

Start

Jan 8, 2013

Primary completion

Mar 21, 2016

Study completion Mar 21, 2016

Sponsor

Lead sponsor
Lexicon PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 3, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to confirm that at least 1 or more doses of telotristat etiprate compared to placebo is effective in reducing the number of daily bowel movements (BMs) from baseline averaged over the 12-week double-blind portion (Treatment Period) of the trial in patients not adequately controlled by current SSA therapy.

Conditions

  • Carcinoid Syndrome

Interventions

  • Telotristat etiprateDrug

    Telotristat etiprate tablets.

  • Placebo-matching telotristat etiprateDrug

    Placebo-matching telotristat etiprate tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Number of Bowel Movements (BMs) Per Day Averaged Over 12 WeeksTime frame: Baseline and 12 Weeks
  2. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Double-Blind Treatment PeriodTime frame: First dose of study drug to within 30 days of last dose of study drug in the Double-Blind Treatment Period (Up to 17.6 Weeks)
  3. Number of Participants With TEAEs in the Open-Label Extension PeriodTime frame: First dose of study drug to within 30 days of last dose of study drug in the Open-Label Extension Period (Up to 54.3 Weeks)

Locations

75 sites in 12 countries. Site status is shown where the registry gives one.

  • Lexicon Investigational Site

    Mobile, Alabama

  • Lexicon Investigational Site

    Palo Alto, California

  • Lexicon Investigational Site

    San Francisco, California

  • Lexicon Investigational Site

    Orlando, Florida

  • Lexicon Investigational Site

    Iowa City, Iowa

  • Lexicon Investigational Site

    Lexington, Kentucky

  • Lexicon Investigational Site

    Kenner, Louisiana

  • Lexicon Investigational Site

    Boston, Massachusetts

  • Lexicon Investigational Site

    Boston, Massachusetts

  • Lexicon Investigational Site

    Omaha, Nebraska

  • Lexicon Investigational Site

    Buffalo, New York

  • Lexicon Investigational Site

    New York, New York

  • Lexicon Investigational Site

    Durham, North Carolina

  • Lexicon Investigational Site

    Philadelphia, Pennsylvania

  • Lexicon Investigational Site

    Fort Worth, Texas

  • Lexicon Investigational Site

    Houston, Texas

  • Lexicon Investigational Site

    McAllen, Texas

  • Lexicon Investigational Site

    Woodville South, Australia

  • Lexicon Investigational Site

    Kogara, New South Wales, Australia

  • Lexicon Investigational Site

    Saint Leanoards, New South Wales, Australia

  • Lexicon Investigational Site

    Herston, Queensland, Australia

  • Lexicon Investigational Site

    Fitzroy, Victoria, Australia

  • Lexicon Investigational Site

    Freemantle, Western Australia, Australia

  • Lexicon Investigational Site

    Edegem, Belgium

  • Lexicon Investigational Site

    Ghent, Belgium

  • Lexicon Investigational Site

    Yvoir, Belgium

  • Lexicon Investigational Site

    Calgary, Alberta, Canada

  • Lexicon Investigational Site

    Halifax, Nova Scotia, Canada

  • Lexicon Investigational Site

    Clichy, France

  • Lexicon Investigational Site

    Lille, France

  • Lexicon Investigational Site

    Lyon, France

  • Lexicon Investigational Site

    Marseille, France

  • Lexicon Investigational Site

    Strasbourg, France

  • Lexicon Investigational Site

    Villejuif, France

  • Lexicon Investigational Site

    Bad Berka, Germany

  • Lexicon Investigational Site

    Berlin, Germany

  • Lexicon Investigational Site

    Essen, Germany

  • Lexicon Investigational Site

    Hamburg, Germany

  • Lexicon Investigational Site

    Heidelberg, Germany

  • Lexicon Investigational Site

    Lübeck, Germany

Showing 40 of 75 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.